Rating History for Eli Lilly (LLY) by BMO Capital
| Date | Analyst | Type | Rating (Past) |
PT (Past) |
Start $ (End $) |
% Chg. | Details |
|---|---|---|---|---|---|---|---|
| 4/18/2024 | Evan David Seigerman | Maintain | Outperform (N/A) |
900.00 (N/A) |
|
Details | |
 |
|||||||
|
|||||||
|
|||||||
|
|||||||
|
|||||||
|
|||||||
|
|||||||
|
|||||||
|
|||||||
| Date | Analyst | Type | Rating (Past) |
PT (Past) |
Start $ (End $) |
% Chg. | Details |
|---|---|---|---|---|---|---|---|
| 4/18/2024 | Evan David Seigerman | Maintain | Outperform (N/A) |
900.00 (N/A) |
|
Details | |
|
|||||||
|
|||||||
|
|||||||
|
|||||||
|
|||||||
|
|||||||
|
|||||||
|
|||||||
|
|||||||
